⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DYN News
Dyne Therapeutics, Inc. Common Stock
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
globenewswire.com
DYN
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
globenewswire.com
DYN
Dyne Therapeutics to Present at Upcoming Investor Conferences
globenewswire.com
DYN
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
globenewswire.com
DYN
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
globenewswire.com
DYN
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
globenewswire.com
DYN